Men Can Document Their Penile Curvature,
Complete a Self-Assessment Questionnaire, Learn About Peyronie's
Disease and Find a Provider Through the App
- Peyronie's Disease assessment and educational
features are meant to empower men with knowledge of the condition
and an understanding of their own penile curvature
-
App to be unveiled to urologists / sexual medicine specialists
and presented as an oral presentation at the 23rd Annual
Fall Scientific Meeting of SMSNA
DUBLIN and BURNSVILLE, Minn., Oct.
27, 2022 /PRNewswire/ -- Endo International
plc (OTC: ENDPQ) and the Sexual Medicine Society of
North America (SMSNA) announced
today the launch of a Peyronie's Self-Assessment application,
available now in the App Store and
Google Play. Peyronie's Disease (PD) is a men's health condition
that may affect 1 in 10 men and can lead to a curvature deformity
with a plaque that can be felt in the penis.
Men who download the free app may use it to:
- Learn more about PD
- Complete a self-assessment questionnaire on the signs and
symptoms of PD
- Document their degree of curvature deformity with a 3D scan and
a 2D image
- Locate a healthcare provider near them
The app is not a diagnostic tool, but men can share the results
with their urologist to help the physician evaluate symptoms.
"For many patients with PD, the condition feels too intimate or
embarrassing to discuss with a doctor," said Gregory Broderick, M.D., founding member of
SMSNA, member of the SMSNA Foundation Board of Directors and an
author of the app presentation. "The new PD app can give men the
facts they may need to help overcome that barrier and speak with
knowledge and even confidence about their curvature to a
urologist."
"The journey to treatment for men with PD can take upward of
seven years," said James P. Tursi,
M.D., Executive Vice President, Global Research & Development
at Endo. "We hope that by putting educational material and a
documentation tool literally in men's hands, they can feel more
empowered to take control of their symptoms and talk to a urologist
about their curvature."
The Peyronie's Self-Assessment app will be unveiled during the
23rd Annual Fall Scientific Meeting of SMSNA, taking
place October 27-30 in Miami, FL, via an oral presentation on
Saturday and a medical booth co-hosted by Endo and SMSNA.
Questionnaires are confidential, and scans are stored on the
mobile device, but only within the app itself. The app does not
share information with any outside party, unless the user chooses
to send results to a urologist, and all data will be permanently
deleted when the app is deleted from a device.
About Peyronie's Disease
Peyronie's Disease (PD) is a
condition in which a buildup of fibrous scar tissue causes a
curvature deformity of the penis. This curvature can be painful
during arousal and intimacy. PD can affect as many as 1 in 10 men
in the U.S., but diagnosis rates remain low because men with PD may
be too uncomfortable to speak up and get help.
About Endo
Endo (OTC: ENDPQ) is a specialty
pharmaceutical company committed to helping everyone we serve live
their best life through the delivery of quality, life-enhancing
therapies. Our decades of proven success come from passionate team
members around the globe collaborating to bring treatments forward.
Together, we boldly transform insights into treatments benefiting
those who need them, when they need them. Learn more
at www.endo.com or connect with us on LinkedIn.
About SMSNA
Established in 1994, the Sexual Medicine
Society of North America (SMSNA)
is a not-for-profit organization of physicians, researchers, and
other allied healthcare professionals committed to advancing the
field of sexual medicine. SMSNA for Patients was established as
SexHealthMatters in 2010 to provide information on a broad range of
sexual health conditions. Learn more at www.smsna.org.
Cautionary Note Regarding Forward-Looking
Statements
Certain information in this press release may be
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and any applicable
Canadian securities legislation, including, but not limited to, the
statements by Drs. Broderick and Tursi, any statements relating to
the application launch and any other statements that refer to
expected, estimated or anticipated future results or that do not
relate solely to historical facts. Statements including words or
phrases such as "believe," "expect," "anticipate," "intend,"
"estimate," "plan," "will," "may," "look forward," "intend,"
"guidance," "future," "potential" or similar expressions are
forward-looking statements. All forward-looking statements in this
communication reflect the Company's current views as of the date of
this communication about its plans, intentions, expectations,
strategies and prospects, which are based on the information
currently available to it and on assumptions it has made. Actual
results may differ materially and adversely from current
expectations based on a number of factors, including, among other
things, the following: the outcome of the Company's contingency
planning and restructuring activities; the timing, impact or
results of any pending or future litigation, investigations,
proceedings or claims, including opioid, tax and antitrust related
matters; actual or contingent liabilities; settlement discussions
or negotiations; the Company's liquidity, financial performance,
cash position and operations; the Company's strategy; risks and
uncertainties associated with Chapter 11 proceedings; the negative
impacts on the Company's businesses as a result of filing for and
operating under Chapter 11 protection; the time, terms and ability
to confirm a sale of the Company's businesses under Section 363 of
the U.S. Bankruptcy Code; the adequacy of the capital resources of
the Company's businesses and the difficulty in forecasting the
liquidity requirements of the operations of the Company's
businesses; the unpredictability of the Company's financial results
while in Chapter 11 proceedings; the Company's ability to discharge
claims in Chapter 11 proceedings; negotiations with the holders of
the Company's indebtedness and its trade creditors and other
significant creditors; risks and uncertainties with performing
under the terms of the restructuring support agreement and any
other arrangement with lenders or creditors while in Chapter 11
proceedings; the Company's ability to conduct business as usual;
the Company's ability to continue to serve customers, suppliers and
other business partners at the high level of service and
performance they have come to expect from the Company; the
Company's ability to continue to pay employees, suppliers and
vendors; the ability to control costs during Chapter 11
proceedings; adverse litigation; the risk that the Company's
Chapter 11 cases may be converted to cases under Chapter 7 of the
Bankruptcy Code; the Company's ability to secure operating capital;
the Company's ability to take advantage of opportunities to acquire
assets with upside potential; the Company's ability to execute on
its strategic plan to pursue, evaluate and close an asset sale of
the Company's businesses pursuant to Section 363 of the U.S.
Bankruptcy Code; the impact of competition, including the loss of
exclusivity and generic competition for VASOSTRICT®; our
ability to satisfy judgments or settlements or pursue appeals
including bonding requirements; our ability to adjust to changing
market conditions; our ability to attract and retain key personnel;
our inability to maintain compliance with financial covenants and
operating obligations which would expose us to potential events of
default under our outstanding indebtedness; our ability to incur
additional debt or equity financing for working capital, capital
expenditures, business development, debt service requirements,
acquisitions or general corporate or other purposes; our ability to
refinance our indebtedness; a significant reduction in our
short-term or long-term revenues which could cause us to be unable
to fund our operations and liquidity needs or repay indebtedness;
supply chain interruptions or difficulties; changes in competitive
or market conditions; changes in legislation or regulatory
developments; our ability to obtain and maintain adequate
protection for our intellectual property rights; the timing and
uncertainty of the results of both the research and development and
regulatory processes, including regulatory decisions, product
recalls, withdrawals and other unusual items; domestic and foreign
health care and cost containment reforms, including government
pricing, tax and reimbursement policies; technological advances and
patents obtained by competitors; the performance, including the
approval, introduction, and consumer and physician acceptance of
new products and the continuing acceptance of currently marketed
products; our ability to integrate any newly acquired products into
our portfolio and achieve any financial or commercial expectations;
the impact that known and unknown side effects may have on market
perception and consumer preference for our products; the
effectiveness of advertising and other promotional campaigns; the
timely and successful implementation of any strategic initiatives;
unfavorable publicity regarding the misuse of opioids; the
uncertainty associated with the identification of and successful
consummation and execution of external corporate development
initiatives and strategic partnering transactions; our ability to
advance our strategic priorities, develop our product pipeline and
continue to develop the market for QWO® and other
products; and our ability to obtain and successfully manufacture,
maintain and distribute a sufficient supply of products to meet
market demand in a timely manner. In addition, U.S. and
international economic conditions, including consumer confidence
and debt levels, inflation, taxation, changes in interest and
currency exchange rates, international relations, capital and
credit availability, the status of financial markets and
institutions, the impact of and response to the ongoing COVID-19
pandemic and the impact of continued economic volatility, can
materially affect our results. Therefore, the reader is cautioned
not to rely on these forward-looking statements. Endo expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required to do so by law.
Logo -
https://mma.prnewswire.com/media/530208/Endo_International_plc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/endo-and-smsna-launch-app-to-provide-peyronies-disease-self-assessment-tool-301660477.html
